Drugs / Symtuza
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | SYMTUZA | — | 2018-07-17 | fda.gov ↗ |
| Approved | EU (EMA) | Symtuza | — | 2017-09-21 | europa.eu ↗ |
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT03696160 | Mar 2019 → Jun 2024 | HIV infectious disease | NEAT ID Foundation | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT05463783 | Mar 2023 → Mar 2025 | HIV infectious disease, obesity disorder | East Carolina University | Unknown | No outcome recorded |
| Phase 4 | NCT04240210 | Sep 2019 → Dec 2021 | HIV infectious disease | Midland Research Group, Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT03685500 | Dec 2018 → Jun 2020 | HIV infectious disease | Fundacion SEIMC-GESIDA | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Symtuza | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04240210 ↗ |
| Known as | D/C/F/TAF | “Symtuza is a combination of darunavir, cobicistat, emtricitabine and tenofovir alafenamide (D/C/F/TAF)” NCT03696160 ↗ |
| Known as | TAF/FTC/DRV/c | “Symtuza® (TAF/FTC/DRV/c)” NCT03685500 ↗ |
| Route | Oral | “taken orally once daily for up to 48 weeks with the addition of food” NCT03696160 ↗ |